ライフサイエンスコーパス: antineoplastic

1 y referred to as cisplatin, is a widely used antineoplastic.

2 rotein contributes to clinical resistance to antineoplastics.

3 oprotein or vitamin C retention modulated by antineoplastics.

4 to additional purine analogues, such as the antineoplastic, 2-chloro-2'-deoxyadenosine (cladribine)

5 DNA damage by FTIs may be critical for their antineoplastic action as a class.

6 -independent properties are important to the antineoplastic action of this class of drugs.

7 rug metformin has been shown to exert strong antineoplastic actions in numerous tumor types, includin

8 nsferase (FTase) inhibitors (FTI) have broad antineoplastic actions targeting both cancer cells and m

9 THZ1 demonstrated pronounced antineoplastic activities both in vitro and in vivo An i

10 Thus, the antineoplastic activities of metformin in pancreatic can

11 mmune responses to invoke both antiviral and antineoplastic activities.

12 ine, a steroid alkaloid that shows promising antineoplastic activities.

13 CL single-chain fragment variable displaying antineoplastic activity against established solid tumors

14 ma, we discovered that ailanthone had potent antineoplastic activity against HCC.

15 Cyclopentenone prostaglandins exhibit unique antineoplastic activity and are potent growth inhibitors

16 active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated th

17 Molecular mechanisms of trastuzumab antineoplastic activity and potential mechanisms contrib

18 According to these results, the antineoplastic activity and safety of TPP(+)C10 warrant

19 ieve sufficient therapeutic windows to exert antineoplastic activity because they are prodrugs that a

20 LY293111 has antineoplastic activity in a variety of preclinical mode

21 asome inhibition and that showed significant antineoplastic activity in a zebrafish embryo model.

22 atment of type II diabetes, clearly exhibits antineoplastic activity in experimental models and has b

23 the p53 tumor suppressor are central to its antineoplastic activity in vivo.

24 diation therapy (RT) was believed to mediate antineoplastic activity mostly (if not only) as a conseq

25 been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in

26 However, the antineoplastic activity of Cu chelators is cytostatic.

27 rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, be

28 de a mechanism for the previously postulated antineoplastic activity of quinolones, and suggest that

29 on of other substrates that are critical for antineoplastic activity of the drug, resulting in drug r

30 enin signaling significantly potentiates the antineoplastic activity of the Plk1 inhibitor BI2536 in

31 o BRAF or MEK1/2 inhibitors and enhanced the antineoplastic activity of these inhibitors.

32 ortezomib or carfilzomib would have stronger antineoplastic activity than combinations currently used

33 rosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD induc

34 cal trials that use this mechanism for their antineoplastic activity, making synthetic lethality one

35 l product halichondrin B, has recently shown antineoplastic activity, with relatively low incidence a

36 this compound or related biguanides may have antineoplastic activity.

37 its effect on bone metabolism and not on its antineoplastic activity.

38 s a novel, selective inhibitor of Mps-1 with antineoplastic activity.

39 nograft models, miR-150 upregulation induced antineoplastic activity.

40 growth factors, and pharmacotherapy with an antineoplastic agent (Erlotinib).

41 The antineoplastic agent benzyl isothiocyanate (BITC) acts b

42 clude the aminoglycoside antibiotics and the antineoplastic agent cisplatin.

43 n vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.

44 our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC.

45 IFN-alpha is an antineoplastic agent in the treatment of several solid a

46 idoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C (MC) under aerobic and

47 ne compound previously used clinically as an antineoplastic agent potentiates the presynaptic functio

48 Doxorubicin (Dox) is a widely used antineoplastic agent that can cause heart failure.

49 o Targeted HSV-1 editing results in a unique antineoplastic agent that enables inflammation without m

50 Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not

51 Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is m

52 Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tu

53 Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action

54 Imatinib, an antineoplastic agent, demonstrated antiinflammatory and

55 inical use of doxorubicin, widely used as an antineoplastic agent, is markedly hampered by severe car

56 the side effects of cisplatin, a widely used antineoplastic agent, major efforts have been made to de

57 )F-FLT) in assessing its effectiveness as an antineoplastic agent.

58 rent clinical assessment of clioquinol as an antineoplastic agent.

59 n attractive candidate for development as an antineoplastic agent.

60 hibitor developed specifically for use as an antineoplastic agent.

61 door for clinical trials evaluating it as an antineoplastic agent.

62 linical information on gallium nitrate as an antineoplastic agent.

63 e II diabetes that has gained interest as an antineoplastic agent.

64 List price increases were lowest (59%) for antineoplastic agents (n = 44), but discounts only offse

65 apeutic tool for hypersensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclita

66 In this study, we examined whether antineoplastic agents 5-fluorouracil (5-FU) and dacarbaz

67 tide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the his

68 e transport of many amphiphilic antibiotics, antineoplastic agents and cytotoxic compounds that are d

69 city that are reported to be associated with antineoplastic agents and discuss their putative mechani

70 ic investigation of PPARdelta antagonists as antineoplastic agents and implicate altered PPARdelta-cy

71 , for a 1-year period, suffered reactions to antineoplastic agents and were referred to the Desensiti

72 in C given before mechanistically dissimilar antineoplastic agents antagonizes therapeutic efficacy i

73 Taxane antineoplastic agents are extensively taken up into hepa

74 -870,893 alone and in combination with other antineoplastic agents are warranted.

75 o asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can incre

76 f advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163)

77 ion can affect the sensitivity of cancers to antineoplastic agents by altering expression of genes cr

78 e induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficac

79 ce or its displacement from the chromatin by antineoplastic agents caused an increase in the levels o

80 Currently, FTIs are being explored as antineoplastic agents for the treatment of several malig

81 orubicin (DOXO) is one of the most effective antineoplastic agents in clinical practice.

82 d consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are recei

83 timal dose for use in combination with other antineoplastic agents in pediatric patients.

84 Approximately 44% of patients received antineoplastic agents in the last 30 days of life throug

85 Desensitization to antineoplastic agents is becoming a standard of care.

86 Antineoplastic agents loaded on 50-100-microm microspher

87 storically, it has been well recognized that antineoplastic agents may have adverse effects on multip

88 as osteosarcoma, for preclinical testing of antineoplastic agents offers significant advantages over

89 antiemetic regimens that are appropriate for antineoplastic agents or radiotherapy being administered

90 mens for adults who receive high-emetic-risk antineoplastic agents or who experience breakthrough nau

91 Targeted antineoplastic agents show great promise in the treatmen

92 The common use of antineoplastic agents such as mitomycin C, doxorubicin,

93 All antineoplastic agents tested caused mitochondrial membra

94 nd colony formation after treatment with all antineoplastic agents tested.

95 In contrast to most other antineoplastic agents that generate reactive oxygen spec

96 Therapy with antineoplastic agents that inhibit EGFR and MEK is frequ

97 at can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy met

98 rease in apoptosis in cells treated with the antineoplastic agents that was not due to up-regulation

99 apy, 51 candidate genes from the pathways of antineoplastic agents were resequenced to identify commo

100 kers has revealed many potential targets for antineoplastic agents, and a particularly important aber

101 argeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges a

102 ncer cell proliferation by aurones and known antineoplastic agents, and in vitro inhibition of tubuli

103 pathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the

104 activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were trea

105 The performance and safety of current antineoplastic agents, particularly water-insoluble drug

106 n deazapurines as antibiotic, antiviral, and antineoplastic agents, the biosynthetic route toward dea

107 ew the development of successful preclinical antineoplastic agents, their associated limitations, and

108 ifaceted approach for the development of new antineoplastic agents.

109 to improve performance and safety of current antineoplastic agents.

110 for designing biocompatible target specific antineoplastic agents.

111 described possible activity of quinolones as antineoplastic agents.

112 lation to cytotoxic chemotherapy or targeted antineoplastic agents.

113 ng beta-lactam antibiotics and antiviral and antineoplastic agents.

114 resistance to paclitaxel and possibly other antineoplastic agents.

115 entify complex III as a potential target for antineoplastic agents.

116 e proposal that these ligands may be used as antineoplastic agents.

117 reast cancer cells to cytoskeletal targeting antineoplastic agents.

118 logic utility as angiogenesis inhibitors and antineoplastic agents.

119 by current or previous treatment with other antineoplastic agents.

120 iatric patients who receive high-emetic-risk antineoplastic agents.

121 tients who are treated with high emetic risk antineoplastic agents.

122 olecules targeting translation initiation as antineoplastic agents.

123 multiple oncoproteins may lead to effective antineoplastic agents.

124 mbining different classes of agents that are antineoplastic and also inhibit bone destruction and inc

125 is a natural product known to possess potent antineoplastic and antiangiogenic properties.

126 Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed act

127 ported data based on more than 100 DPTs with antineoplastic and biological agents (paclitaxel, oxalip

128 e regarding drug provocation test (DPT) with antineoplastic and biological agents is scarce.

129 poptotic factor and is a novel target of the antineoplastic and cardiomyopathic drug doxorubicin (Dox

130 rting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents [EROCA]; NCT0

131 95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents.

132 nd modulator of protein kinase C that exerts antineoplastic and immunomodulatory activities both in v

133 ic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast

134 is a cytokine with potent immunoregulatory, antineoplastic, and antiviral properties.

135 folate metabolism and an important target of antineoplastic, antimicrobial, and antiinflammatory drug

136 een 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antip

137 cid conjugated to cytotoxics, a new class of antineoplastics, are transported into cells via FR-media

138 also sustain copy number loss in GBM through antineoplastic assay and identified A2BP1 (ataxin 2 bind

139 he utility of our method using zebrafish for antineoplastic candidate drug identification and suggest

140 CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)

141 Antineoplastic chemotherapeutic agents may indirectly ac

142 e tested the effects of different classes of antineoplastic chemotherapeutic agents used in low noncy

143 Age is not a contraindication of antineoplastic chemotherapy as long as it is based on ph

144 itors to mTOR inhibitors, as alternatives to antineoplastic chemotherapy, along with the use of antih

145 history of gastric bleeding, breast cancer, antineoplastic chemotherapy, and prednisone use presente

146 orbidity and mortality in patients receiving antineoplastic chemotherapy.

147 d to the development of novel strategies for antineoplastic chemotherapy.

148 a nigriventer (PnV) is a potential source of antineoplastic components with activity in glioblastoma

149 arsenic trioxide (As(2)O(3)), a very potent antineoplastic compound for the treatment of acute promy

150 amoxicillin, cephalexin and cefadroxil, the antineoplastics delta-aminolevulinic acid (delta-ALA) an

151 noic acid (OA-NO(2)) in combination with the antineoplastic DNA-damaging agents doxorubicin, cisplati

152 gest a potential role for S-nitrosylation in antineoplastic drug action.

153 nged exposure of lung-resident tumors to the antineoplastic drug and reduced local toxicity.

154 tudy, we monitored the cellular responses to antineoplastic drug at a single cell basis with Raman sp

155 tential to augment preclinical evaluation of antineoplastic drug candidates for these malignancies.

156 The antineoplastic drug carmofur is shown to inhibit the SAR

157 Here we show that the antineoplastic drug carmofur, which is used in the clini

158 effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site wit

159 Carmofur is an antineoplastic drug containing an electrophilic carbonyl

160 is has recently become a suitable target for antineoplastic drug development.

161 has served as an important lead compound in antineoplastic drug discovery.

162 rmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated.

163 I) chloride hexahydrate (CoCl2.6H2O) and the antineoplastic drug doxorubicin.

164 Nortriptyline further synergizes with the antineoplastic drug gemcitabine to effectively suppress

165 Ethonafide is an anthracene-based antineoplastic drug similar to MIT.

166 The antineoplastic drug sorafenib (BAY 43-9006) is a multiki

167 n over the past decade, yet most preclinical antineoplastic drug testing is still reliant on conventi

168 he nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced

169 Paclitaxel is a microtubule-targeting antineoplastic drug widely used in human cancers.

170 Paclitaxel (PTX) is an antineoplastic drug widely used in treatments for ovaria

171 The efficacy of ifosfamide (IFO), an antineoplastic drug, is severely limited by a high incid

172 immune cells with a highly immunosuppressive antineoplastic drug.

173 We found that antineoplastic drugs become concentrated in specific pro

174 The therapeutic efficacy of the widely used antineoplastic drugs doxorubicin, cisplatin, vincristine

175 dentification, optimization and synthesis of antineoplastic drugs from PnV molecules may lead to a ne

176 Prices of topical antineoplastic drugs had the greatest mean absolute and

177 Moreover, the local toxicity induced by antineoplastic drugs is considered a major obstacle for

178 side effect associated with cancer-treating antineoplastic drugs is the development of neuropathic p

179 ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 muM doxorubicin

180 witch is a rational target for the design of antineoplastic drugs that selectively inhibit PKCepsilon

181 so induced partial cross-resistance to other antineoplastic drugs.

182 making the tumor cells further resistant to antineoplastic drugs.

183 to improve the development and evaluation of antineoplastic drugs.

184 ity and alter the pharmacokinetic profile of antineoplastic drugs.

185 ffects of reactive oxygen species-generating antineoplastic drugs.

186 lective, small-molecule kinase inhibitors as antineoplastic drugs.

187 ng strategies as a means of developing novel antineoplastic drugs.

188 n countries and has been reported to have an antineoplastic effect both in vitro and in vivo.

189 sufficient and successful strategy to induce antineoplastic effect in hematologic tumors.

190 cal data suggest that folic acid may have an antineoplastic effect in the large intestine.

191 We conclude that the antineoplastic effect of Combo NP works by first targeti

192 RhoB, a mediator of the antineoplastic effect of FTIs and a protein inducible by

193 n; however, their relative importance in the antineoplastic effect of FTIs may vary in different cell

194 ies support the antiviral, antifibrotic, and antineoplastic effect of interferon therapy.

195 Resistant starch has been associated with an antineoplastic effect on the colon.

196 molecular weight heparins (LMWHs), exert an antineoplastic effect through multiple mechanisms, inclu

197 This strong antineoplastic effect was successfully recapitulated by

198 uggest that some alleles of ATM may exert an antineoplastic effect, perhaps by altering the activity

199 apacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy

200 in plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.

201 understanding of the action of vitamin D3 in antineoplastic effects and the role of Beclin1 in regula

202 Metformin exhibits antiproliferative and antineoplastic effects associated with inhibition of mam

203 We have previously demonstrated potent antineoplastic effects for the PI3Kalpha selective inhib

204 esponse it engenders produce potent, lasting antineoplastic effects in animal tumor models.

205 HDACIs have antineoplastic effects in preclinical and clinical trial

206 tuent of licorice, has been shown to exhibit antineoplastic effects in prostate cancer cell lines by

207 Whether epigenetic drugs produce antineoplastic effects in vivo in patients with ASM and

208 Notably, these antineoplastic effects induced by either shRNAs or small

209 at least one explanation for the remarkable antineoplastic effects observed by some ES tumor patient

210 The antineoplastic effects of alpelisib were substantially e

211 The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch

212 incorporated 5-FU plays a major role in the antineoplastic effects of FdUrd.

213 se inhibitor (GSi) cocktail demonstrated the antineoplastic effects of GSi in a subset of CCA and led

214 The mechanisms of generation of the antineoplastic effects of interferons (IFNs) in malignan

215 and help to explain previous reports on the antineoplastic effects of natural products containing su

216 However, the mechanisms underlying the antineoplastic effects of NSAIDs remain unclear.

217 To discriminate between antineoplastic effects of NSAIDs that are mediated by ei

218 t part of the anti-inflammatory and putative antineoplastic effects of PGJ(2) may be mediated through

219 we show that serine withdrawal increases the antineoplastic effects of phenformin (a potent biguanide

220 e autophagy pathway dramatically augment the antineoplastic effects of SAHA in CML cell lines and pri

221 on, AK295 did not interfere with the primary antineoplastic effects of Taxol on microtubules and cell

222 In this study, we investigated the antineoplastic effects of the PPARgamma agonist pioglita

223 Mnk kinase pathway in the generation of the antineoplastic effects of type I IFNs in Jak2V617F-depen

224 evertheless, the mechanisms underlying these antineoplastic effects remain poorly understood.

225 e mechanism by which HDAC inhibitors mediate antineoplastic effects remains elusive.

226 No antineoplastic effects were induced by pioglitazone in g

227 I)-containing complexes have shown promising antineoplastic effects when tested in a host of malignan

228 )-independent pathways in celecoxib-mediated antineoplastic effects, the following two issues remain

229 models suggest that thiazolidinediones have antineoplastic effects, whereas in vivo studies have pro

230 replacement, anti-inflammatory effects, and antineoplastic effects.

231 fn2 and Slfn3, Slfn5 also exhibits important antineoplastic effects.

232 entrations of this compound are required for antineoplastic effects.

233 etabolic effects, PPARgamma agonists exhibit antineoplastic effects.

234 The antineoplastic efficacy of anthracyclines is limited by

235 cted GBM cells is a core requirement for the antineoplastic efficacy of PVSRIPO.

236 e, a beta-blocker, an antidepressant, and an antineoplastic) frequently found in surface water were s

237 t mice revealed that this protein exerts its antineoplastic function through the regulation of the in

238 link the biosynthetic origins of the potent antineoplastic gymnopeptides to the borosin natural prod

239 Azidothymidine was studied as an antineoplastic in the 1990s, but despite promising in vi

240 As a potential target for antineoplastic intervention, we designed IMPCH inhibitor

241 aling; inhibiting it is a valid strategy for antineoplastic intervention.

242 PBK/TOPK may therefore be a valid target for antineoplastic kinase inhibitors to sensitize tumor cell

243 We have elucidated the antineoplastic mechanism for Aurora B kinase inhibitors

244 Targeting Sox2(+) cells with the antineoplastic mithramycin abrogated tumor growth.

245 These findings suggest a novel antineoplastic molecular effect of mesalamine.

246 esize and carry out a formulation with these antineoplastic molecules for clinical trials.

247 Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrap

248 ole in metabolic activation of antiviral and antineoplastic nucleoside-analog prodrugs.

249 As established previously, NN stimulated antineoplastic or cytostatic signaling and phenotype in

250 role in detoxifying carcinogens, activating antineoplastic prodrugs, metabolizing chemotherapeutic a

251 therapy for bipolar disorders, has selective antineoplastic properties against cancers that harbor th

252 normal stromal cells, MSCs possess intrinsic antineoplastic properties and that this stem cell popula

253 esponse modifiers that independently display antineoplastic properties can enhance TRAIL-induced apop

254 s problem is identifying agents that display antineoplastic properties concomitant with their immunos

255 genic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the

256 polyunsaturated fatty acids (PUFAs) may have antineoplastic properties in the colon.

257 A range of antineoplastic properties is attributed to aspirin, thou

258 The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line dru

259 omoting biomolecules and the antioxidant and antineoplastic properties of milk.

260 idal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do no

261 erferons (IFNs) have important antiviral and antineoplastic properties, but the precise mechanisms re

262 r normally resistant tumors sensitive to its antineoplastic properties.

263 quaternary benzophenanthridine alkaloid with antineoplastic properties.

264 nge of physiological activity as well as its antineoplastic properties.

265 and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days a

266 comitant chemotherapy delivery and increased antineoplastic response in murine models of PDA.

267 k was found between CP110 and CDK2 inhibitor antineoplastic response.

268 N signaling and the generation of type I IFN antineoplastic responses.

269 This reveals a novel antineoplastic role of AID that can be triggered by inhi

270 dered in the design of chemopreventative and antineoplastic strategies that involve inhibition of Bcl

271 e that targeting TRPC6 in HCC may be a novel antineoplastic strategy, especially combined with chemot

272 stress-signaling pathway represent potential antineoplastic targets.

273 s and has emerged as a productive target for antineoplastic therapeutic intervention.

274 a is a potential target for developing novel antineoplastic therapeutic strategies.

275 gimens, new immunosuppressive therapies, new antineoplastic therapies administered before hematopoiet

276 ical interactions between antiretroviral and antineoplastic therapies and consider how to combine ant

277 parameters, discontinuation of all previous antineoplastic therapies at least 6 weeks before interve

278 Antineoplastic therapies offer significant benefit, but

279 Two signaling pathways are activated by antineoplastic therapies that damage DNA and stall repli

280 temporary development of rationally designed antineoplastic therapies, cladribine was identified as a

281 t failure and a debilitating complication of antineoplastic therapies.

282 ugs inhibiting MTOR are increasingly used in antineoplastic therapies.

283 d bone metastases were stratified by type of antineoplastic therapy received and randomly assigned to

284 ndomized controlled trials in which standard antineoplastic therapy was used with and without bevaciz

285 ession is a life-threatening complication of antineoplastic therapy, but treatment is restricted to a

286 Interactions among antineoplastic therapy, cancer type, and COVID-19 are co

287 ion by antibodies may be a clinically viable antineoplastic therapy, particularly for melanoma.

288 at is associated with decreased tolerance to antineoplastic therapy, poor prognosis and accelerated d

289 xicities of NSAIDs have limited their use as antineoplastic therapy.

290 fecting tumors represent a novel strategy of antineoplastic therapy.

291 nd as a predictive marker of the response to antineoplastic therapy.

292 history of previous hematologic disorder or antineoplastic therapy.

293 Tubulin is a well-established target of antineoplastic therapy; however, tubulin-targeting agent

294 To study the genotoxic effects of antineoplastic treatment in children, we performed a com

295 ontributed to foster HuR inhibition as valid antineoplastic treatment in thyroid cancer, highlighting

296 ive needs of older cancer patients receiving antineoplastic treatment.

297 Changes in antineoplastic treatments and transplant practices are d

298 Therefore, NCL is an attractive target for antineoplastic treatments.

299 plementation of (45)Ti-PET in titanium-based antineoplastics using the showcase compound [(45)Ti](sal

300 tinely been enrolled onto phase I studies of antineoplastics without clinically meaningful increase i